The former CEO Dr. Hans Loibner will continue to support the Company as senior advisor. Press release Presseaussendung
APEIRON strengthens its proprietary Cbl-b portfolio with cutting edge immunotherapy technology developed at IMBA. Presseaussendung Press Release
The European Investment Bank blog is featuring APEIRON Biologics AG in following article: http://www.eib.org/stories/new-cancer-treatments
APEIRON Biologics AG today announced it would present data on two of its key programs in three poster presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, being held on June 1-5, 2018, in Chicago, IL. Presseaussendung Press Release
APEIRON Biologics AG and Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that the companies received the first milestone payment from Sanofi under a 3-party alliance signed in August 2015. Press release Presseaussendung
APEIRON Biologics AG today announced that it will present at Biotech Showcase™ 2018, to be held January 8–10 at the Hilton San Francisco Union Square during one of the most important weeks in healthcare investing. Press release Presseaussendung
APEIRON Biologics AG today announced the publication of a successful clinical study in high-risk neuroblastoma patients in the December issue of mAbs, a prominent journal in the monoclonal antibody field. Press release Presseaussendung
APEIRON Biologics AG appointed Peter Llewellyn-Davies as new Chief Financial Officer and Chief Business Officer. The biotech and financial expert Llewellyn-Davies is considered an internationally experienced and recognized transaction specialist. After marketing approval of APEIRON’s immunotherapeutic against neuroblastoma the appointment of this strategically important role should prepare the company for its next phase of growth….